What's Going On With Iovance Biotherapeutics Stock?
Portfolio Pulse from Adam Eckert
Iovance Biotherapeutics' stock is trading higher after the FDA accepted its Biologics License Application for lifileucel, a TIL therapy for advanced melanoma patients. Analysts from Stifel, Chardan Capital, and HC Wainwright & Co. maintained Buy ratings and raised price targets.
May 30, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics' stock is up after the FDA accepted its lifileucel application, and analysts maintained Buy ratings and raised price targets.
The FDA's acceptance of Iovance Biotherapeutics' lifileucel application is a significant milestone for the company, as it brings the therapy closer to potential approval and commercialization. This positive news has led to analysts maintaining Buy ratings and raising price targets, which in turn has boosted the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100